Inhibition of these transport proteins on the surface of AML cells by quizartinib would result in sensitization to ABC protein substrate chemotherapy drugs, and co-inhibition of FLT3 and ABCG2 could improve outcomes. The gene discussed is FLT3; the disease is acute myeloid leukemia.